Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition

FDA approves Regeneron and Sanofi's Dupixent for allergic fungal sinusitis in patients 6 years and older with prior surgery history.

Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and ...
The Bluffton Icon

Weekend Doctor: When is sinus surgery needed?

Otolaryngology, Head and Neck Surgeon, ENT Specialists of Northwest Ohio Sinus problems are a common source of discomfort for millions of adults worldwide. Chronic rhinosinusitis (CRS)—persistent ...
Frontiers

Real-world sinonasal outcomes in patients with primary diffuse chronic rhinosinusitis treated with mepolizumab across polyp phenotypes

Mepolizumab blocks IL-5, targeting eosinophilic type-2 inflammation. Due to existing phenotype driven patient selection, evidence of its effectiveness in primary diffuse CRS and CRS without nasal ...
EurekAlert!

Study reveals weight loss medications may improve outcomes for chronic sinus disease patients

A new study published in Otolaryngology–Head and Neck Surgery, the peer-reviewed journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation, reveals that glucagon-like ...
Kaleido Scope

Can a sinus infection invade the brain? What to know about sinusitis this cold and flu season

“It doesn’t happen often, but a sinus infection can spread beyond the nasal passages and into the brain,” said Elizabeth Liptrap, M.D., assistant professor in the Department of Neurosurgery. “When ...
Healio

Tezepelumab outperforms other biologics in chronic rhinosinusitis with nasal polyps

Please provide your email address to receive an email when new articles are posted on . The analysis compared results from the WAYPOINT, SINUS-52 and SYNAPSE studies. Tezepelumab outperformed ...
MarketWatch

Insmed Ends Sinus Drug Development on Failed Study, Acquires Antibody Treatment

Insmed is discontinuing development of brensocatib in chronic rhinosinusitis without nasal polyps. The Bridgewater, N.J.-based pharmaceutical company also said Wednesday that it was acquiring INS1148, ...
Bloomberg L.P.

Insmed Sinks After Brensocatib Fails Trial for Sinus Condition

Insmed Inc. shares sunk in late trading Wednesday after the company said its drug to treat a sinus condition failed in a mid-stage trial — a rare setback for the fast-growing biotech. The company had ...
Prevention

Nasal Spray Recalled Over Mold, ‘Life-Threatening Infection’ Concerns, FDA Reports

ReBoost Nasal Spray is being recalled over yeast/mold and microbial contamination. Using the recalled products may have serious adverse health consequences. Read on for details on the specific lot ...
AOL

Nasal Spray Recalled Nationwide Over Mold, Potential ‘Life-Threatening Infection’

Sat, December 13, 2025 at 1:30 PM UTC The product is a homeopathic nasal spray used to help combat a slew of respiratory-related symptoms, from sinus congestion to nasal itching, per the FDA. Only a ...